CRISPR Therapeutics Reports Widened Annual Loss, Increased CASGEVY Program Costs, and New Patent Litigation

summarizeSummary

CRISPR Therapeutics filed its annual 10-K, revealing a significantly widened net loss for 2025, a substantial increase in collaboration expenses for its approved CASGEVY therapy, and a new patent infringement lawsuit against CASGEVY, alongside ongoing clinical pipeline progress and significant equity raises.

check_boxKey Events

• Widened Net Loss and Revenue Decline

  The company reported a net loss of $581.6 million for 2025, a significant increase from $366.3 million in 2024. Collaboration revenue dropped to zero in 2025 from $35.0 million in 2024, primarily due to non-recurring milestone payments.

• Increased CASGEVY Program Costs

  Collaboration expenses, net, surged to $213.5 million in 2025 from $120.7 million in 2024. This increase is primarily attributable to the end of the deferral limit on the CASGEVY program, requiring the company to fully absorb its 40% share of increased commercial and manufacturing costs.

• New Patent Infringement Lawsuit Against CASGEVY

  ToolGen, Inc. initiated a lawsuit in Q4 2025 alleging patent infringement by CASGEVY, introducing a significant legal risk to the commercialization of the company's only approved therapy.

• Significant Equity Financing and New Collaboration

  CRISPR Therapeutics raised $401.3 million in gross proceeds through ATM offerings in 2025, including a new $600 million ATM program. Additionally, it issued 1,842,105 common shares (valued at approximately $70.0 million) as part of a new collaboration agreement with Sirius Therapeutics in May 2025 for siRNA-based programs.

auto_awesomeAnalysis

CRISPR Therapeutics' annual 10-K filing reveals a challenging financial year marked by a significantly widened net loss and a substantial increase in collaboration expenses for its key approved therapy, CASGEVY. The cessation of cost deferrals for the CASGEVY program means the company is now fully absorbing its 40% share of expenses, impacting profitability. A new patent infringement lawsuit against CASGEVY introduces a material legal risk to its commercialization. While the company continues to advance its pipeline with positive clinical updates for CASGEVY in pediatric populations, CTX310 in cardiovascular disease, and Zugo-cel in autoimmune and oncology indications, and secured a new collaboration with Sirius Therapeutics, these positive developments are overshadowed by the financial deterioration and the new legal challenge. Investors should monitor the outcome of the patent litigation and the company's ability to manage increased operational costs for CASGEVY while progressing its broader pipeline.